Abbott Implants Patient With Dual-Chamber Leadless Pacemaker
07 Fevereiro 2022 - 11:41AM
Dow Jones News
By Matt Grossman
Abbott Laboratories said that a patient in a clinical trial of
new cardiac technology has been implanted with a dual-chamber
leadless pacemaker, an innovation that Abbott said could reduce
complications and recovery times from pacemaker procedures.
Leadless pacemakers are implanted into the heart in a procedure
that is minimally invasive compared with traditional pacemakers,
Abbott said. In the past, however, the approach was limited to
single-chamber pacemakers.
The company's new technology allows two leadless pacemakers to
regulate the heart rate synchronously by enabling communication
between the devices, Abbott said.
The implant took place at a Prague hospital, Abbott said. It was
part of a study that eventually aims to enroll up to 550 patients
at sites world-wide.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
February 07, 2022 09:26 ET (14:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
